US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 10:10:35 Source:opinionsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Seoul AI summit opens with companies including Google, Meta, OpenAI pledging to develop AI safely
Next:Garcia, Winker go deep as Nats end slide, beat struggling Twins 12
You may also like
- The bodies of 4 men and 2 women were found strangled, piled up in Mexican resort of Acapulco
- Biden could miss the deadline for the November ballot in Alabama
- AAC Commissioner Tim Pernetti says CFP expansion is encouraging and there is room for more growth
- Biden heads to his hometown of Scranton, Pennsylvania, to talk about taxes
- Microsoft's AI chatbot will remember everything you do on a PC
- Skubal throws 5 scoreless innings, Canha homers and Tigers beat Twins 8
- Wrexham eyes another promotion, this time to 3rd tier of English soccer
- Knicks top Nets 111
- Poland arrests sabotage suspects and warns of potential hostile acts by Russia